Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase I
about
Therapeutic Potential of Hyporesponsive CD4(+) T Cells in AutoimmunityImmune-regulatory mechanisms in systemic autoimmune and rheumatic diseasesAntigen-based immunotherapy for autoimmune disease: current statusSkewed Helper T-Cell Responses to IL-12 Family Cytokines Produced by Antigen-Presenting Cells and the Genetic Background in Behcet's DiseaseHeat shock protein bystander antigens for peptide immunotherapy in autoimmune diseaseHeat shock proteins (HSPs) in the homeostasis of regulatory T cells (Tregs)Tolerization against atherosclerosis using heat shock protein 60Alarmins: awaiting a clinical responseHuman platelet antigen (HPA)-1a peptides do not reliably suppress anti-HPA-1a responses using a humanized severe combined immunodeficiency (SCID) mouse model.Heat shock protein-derived T-cell epitopes contribute to autoimmune inflammation in pediatric Crohn's disease.A towards-multidimensional screening approach to predict candidate genes of rheumatoid arthritis based on SNP, structural and functional annotations.T cell recognition of naturally presented epitopes of self-heat shock protein 70.Immune responses in age-related macular degeneration and a possible long-term therapeutic strategy for preventionCord blood CD4+ T cells respond to self heat shock protein 60 (HSP60)Antigen-specific immunotherapy for type 1 diabetes: maximizing the potential.Sequential transcriptional changes dictate safe and effective antigen-specific immunotherapy.Prophylactic Injection of Recombinant Alpha-Enolase Reduces Arthritis Severity in the Collagen-Induced Arthritis Mice ModelInflammatory Mechanisms of Age-related Macular Degeneration.A circulating reservoir of pathogenic-like CD4+ T cells shares a genetic and phenotypic signature with the inflamed synovial micro-environment.Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritisHeat-shock proteins in autoimmunity.Vaccination with endosomal unknown epitopes produces therapeutic response in rheumatoid arthritis patients and modulates adjuvant arthritis of rats.APL1, an altered peptide ligand derived from human heat-shock protein 60, increases the frequency of Tregs and its suppressive capacity against antigen responding effector CD4 + T cells from rheumatoid arthritis patientsHuman Hsp40 proteins, DNAJA1 and DNAJA2, as potential targets of the immune response triggered by bacterial DnaJ in rheumatoid arthritis.Treg inducing adjuvants for therapeutic vaccination against chronic inflammatory diseasesCan rheumatoid arthritis be prevented?Combination peptide immunotherapy suppresses antibody and helper T-cell responses to the RhD protein in HLA-transgenic mice.Molecular chaperones and protein-folding catalysts as intercellular signaling regulators in immunity and inflammation.Treating arthritis by immunomodulation: is there a role for regulatory T cells?Antigen-specific immunotherapy of autoimmune and allergic diseasesInduction of immune tolerance in the treatment of rheumatoid arthritis.Anti-citrullinated protein antibodies (ACPA) in early rheumatoid arthritis.Peptide immunotherapy for childhood allergy - addressing translational challenges.Heat shock proteins are therapeutic targets in autoimmune diseases and other chronic inflammatory conditions.Dendritic cells and the promise of antigen-specific therapy in rheumatoid arthritis.Monoclonal antibody treatments for rheumatoid arthritis.Heat shock proteins can be targets of regulatory T cells for therapeutic intervention in rheumatoid arthritis.Pathophysiology of JIA-associated uveitis.Polymer-based vehicles for therapeutic peptide delivery.Intercentre variance in patient reported outcomes is lower than objective rheumatoid arthritis activity measures: a cross-sectional study.
P2860
Q26781243-8D12DE36-48BE-4633-B00C-689373D0F207Q26823714-EBB05093-2263-4977-A001-41F7AAF51880Q26852915-175CDA7F-A929-4AB6-A891-C1E8617EF9D2Q26866098-B99A92DA-10D0-4146-A4E7-C8C63CB890FAQ27008837-5CA0BBC2-DE78-44DC-89CF-E02BDA86464DQ28069922-FD52B9D8-A90A-4C2F-8A08-A349C297CDC6Q28081051-BD881D58-9049-47F2-82AC-B867B3325D4BQ30523797-F5635FB4-5D6E-4FB0-83EA-BDA6222C561CQ33411662-D129E799-AAE1-4610-9063-501FD557B682Q33514815-5BE91BF9-7ECA-49F4-9CDB-21BA2D57D585Q33667497-36DC944F-5FF5-4619-86C5-A1EDA4B117E8Q33700807-D28FC18E-0D50-4F79-973F-A18972CDF70FQ33758205-81916760-78EE-4452-94A0-DE0118C2002AQ34023284-AFA1DD17-2922-43B5-A220-06C603596136Q34082782-2B7C231B-6F67-48BE-951D-E389DE933B84Q34205503-66FECBA9-AC54-4ECE-BCC6-4CD360851B1CQ35753838-F8A4757C-3BE9-443C-9D29-C84F8EA73BF5Q35755942-55F23E90-280C-4AF6-B6C5-D43673EB7461Q36577387-C34E9FB4-126B-40B7-BCBF-7B8A40890922Q36673061-6F206899-66C9-4FAC-B830-D7B1EFD66653Q36899453-7B42222F-8590-479A-B506-AA81D6DAE486Q36980842-56D76C1B-F67B-4C75-B9A1-62BDCB38C88CQ37004617-EF5DB5CA-E27F-4CDF-9B1A-A6FD1AB105D7Q37099491-9FE90876-B03B-4E06-855A-1598C4D2E9D3Q37105550-ECFA37E7-4EB7-460B-93D8-E62C2DEAF970Q37589108-1C9AB062-102F-4A5A-9F9C-15B4409D2579Q37618940-087E6AE8-0583-41B5-BE88-7DB4BA905BCFQ37743010-7AA9DBDF-DD06-4BA6-BC92-D4209BD64A8AQ37750140-223CA50E-2DA3-4C9F-B59C-21830D79C45EQ37790023-FC13A5C1-21BF-4F9F-B1EE-0B37EE6327DAQ37862081-7966E3C1-4B46-4172-B20D-53668DD87F7DQ37898025-239FF0B8-FAEE-466E-B7DC-7D48AEBEFE45Q37992746-C632EE41-8AD4-4EED-8899-7450DF168D26Q38026064-3BFF897C-7BE4-4449-A709-AA4D63C883CBQ38078552-D2DCB36B-3989-4B9C-A0BF-650206077ED1Q38116065-12173743-B44F-4064-B26B-BB514C6073ABQ38122210-8718A333-B3C4-44F4-B873-8E3E56995CE9Q38225611-A97C7A67-5996-4B85-A32A-ABFE0032AF3EQ38645362-C7B70A33-D08B-4914-A6EC-86902EC6FBD2Q38748219-696729F7-AC46-48CC-B31C-C43F400209E5
P2860
Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase I
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
2009年论文
@zh
2009年论文
@zh-cn
name
Epitope-specific immunotherapy ...... cebo-controlled, pilot phase I
@en
type
label
Epitope-specific immunotherapy ...... cebo-controlled, pilot phase I
@en
prefLabel
Epitope-specific immunotherapy ...... cebo-controlled, pilot phase I
@en
P2093
P356
P1476
Epitope-specific immunotherapy ...... cebo-controlled, pilot phase I
@en
P2093
Alan J Kivitz
Arthur Kavanaugh
Berent A Prakken
Carolyn Dennehey
Diane Amox
Elissa Keogh
Eric L Matteson
Ernesto Santana
Eva C Koffeman
Femke van Wijk
P304
P356
10.1002/ART.24916
P577
2009-11-01T00:00:00Z